Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDICAID-LIKE DRUG PRICE REBATES WOULD BE EXTENDED TO PHS- FUNDED PROGRAMS UNDER MEASURE DRAFTED BY SEN. KENNEDY AS AMENDMENT TO HHS APPROPRIATIONS BILL

Executive Summary

Pharmaceutical manufacturers would be required to provide Medicaid-like drug price rebates to Public Health Service programs under legislation drafted by Sen. Kennedy (D-Mass.). Prepared as an amendment to the fiscal 1992 HHS appropriations bill, Kennedy's measure would require manufacturers of prescription drugs and biologicals purchased by PHS-funded "entities" to provide rebates that effectively would reduce the price to levels paid by Medicaid. The programs that would receive the rebates under the bill include migrant health centers; community health centers; alcohol and drug treatment or mental health centers; family planning clinics; and black lung clinics that receive PHS funding. Under the legislation, manufacturers may not sell to PHS-funded entities unless they provide price rebates. The amendment has not been introduced by Kennedy because the appropriations bill has yet to be called up on the Senate floor. Debate on the HHS appropriations bill reportedly has been blocked by Senate Republicans. Unlike the Medicaid rebate law, Kennedy's amendment does not require rebates sufficient to lower PHS' costs to manufacturers' "best price" levels. Instead it requires HHS to issue regulations requiring that PHS-funded programs pay no more than Medicaid for prescription drugs. The bill further requires HHS to "attempt" to negotiate with manufacturers to obtain rebates sufficient to reduce prices to levels "comparable to or lower than the price charged [to the PHS] entities by the manufacturer on Sept. 1, 1990, increased by the fiscal year 1991 consumer price index." Reportedly, many PHS-funded programs that are the focus of the bill are charity programs that formerly benefited from deeply discounted drug prices from several manufacturers. However, the eleemosynary discounts were discontinued after the Medicaid legislation was enacted. The companies raised their prices to the programs to avoid having to offer similar prices to the larger Medicaid market, as would be required under the Medicaid legislation's best price provision. The Pharmaceutical Manufacturers Association opposes the Kennedy amendment, and a number of Republican senators reportedly have holds on it. PMA wants to add a provision stipulating that prices offered to PHS-funded programs be exempt from Medicaid best price calculations. The industry was successful in persuading Kennedy's staff to remove a provision from an earlier draft that would have authorized HHS to fine companies $ 10,000 a day for not offering rebates to PHS.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel